STOCK TITAN

Catalyst Pharmaceuticals Inc - CPRX STOCK NEWS

Welcome to our dedicated page for Catalyst Pharmaceuticals news (Ticker: CPRX), a resource for investors and traders seeking the latest updates and insights on Catalyst Pharmaceuticals stock.

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a biopharmaceutical leader focused on rare neuromuscular and neurological disorders, including its FDA-approved therapy for Lambert-Eaton Myasthenic Syndrome (LEMS). This page provides official updates and analysis of Catalyst's developments in drug commercialization, regulatory milestones, and clinical research.

Investors and healthcare professionals can monitor critical updates including FDA decisions, clinical trial progress, and strategic partnerships. All content is sourced from verified filings, press releases, and reputable financial analysis to ensure accuracy.

Key focus areas include developments around Firdapse® commercialization, pipeline advancements for CPP-115, and regulatory strategies for orphan drug designations. The curated news collection enables efficient tracking of Catalyst's position in the competitive rare disease therapeutics market.

Bookmark this page for consolidated access to Catalyst's latest business and scientific developments. Check regularly for updates impacting the company's growth trajectory in a sector where regulatory approvals directly influence market performance.

Rhea-AI Summary
Catalyst Pharmaceuticals announces that a study reveals a significant underdiagnosis of Lambert-Eaton myasthenic syndrome (LEMS) in US patients with small cell lung cancer (SCLC). While previous estimates suggest that 3% of SCLC patients have LEMS, this study found that only 0.16-0.24% of SCLC patients had LEMS claims, indicating a 10-fold underdiagnosis. The study suggests that non-specific LEMS symptoms may have been attributed to SCLC, leading to underdiagnosis. The prevalence of LEMS is now estimated to be 3,600 to 5,400 people in the US.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.6%
Tags
none
-
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. (CPRX) announces multiple abstracts on FYCOMPA® (perampanel) CIII to be presented at the 35th International Epilepsy Congress, highlighting its use in treating focal and generalized epilepsy in diverse patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.13%
Tags
none
-
Rhea-AI Summary
Catalyst Pharmaceuticals achieves record Q2 2023 total net revenues of $99.6 million, with a 22% YoY increase in FIRDAPSE net revenues. They also report a Q2 GAAP EPS diluted of $0.33 compared to $0.20 for Q2 2022. The company completed the acquisition of the North American license for Vamorolone and submitted an sNDA for FIRDAPSE seeking to increase the maximum indicated dose. They have raised their full-year 2023 total revenue guidance to between $380 million and $390 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.37%
Tags
Rhea-AI Summary
Catalyst Pharmaceuticals announces that Patrick J. McEnany, Co-Founder, Chairman, and CEO, will retire from his position by the end of 2023. He will continue to serve as non-Executive Chairman of the Board. The Board has initiated a search for his successor as CEO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
none
-
Rhea-AI Summary
Catalyst Pharmaceuticals, Inc. will release its second-quarter 2023 financial results on August 9, 2023, and host a conference call and webcast on August 10, 2023, to discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.88%
Tags
conferences earnings
-
Rhea-AI Summary
Catalyst Pharmaceuticals has acquired an exclusive license for North America for vamorolone, a potential treatment for Duchenne Muscular Dystrophy (DMD). Vamorolone has shown efficacy in clinical studies with reduced side effects and benefits for DMD patients. The drug has received FDA Orphan Drug and Fast Track designations, with a PDUFA action date of October 26, 2023. Catalyst expects to launch vamorolone in the U.S. early in Q1 2024, subject to regulatory approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.44%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.78%
Tags
-
Rhea-AI Summary
Catalyst Pharmaceuticals announces the appointment of Tamar Thompson to its Board of Directors. Thompson brings extensive experience in rare diseases and health policy. Catalyst expects her contributions to align with their growth strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
management
Rhea-AI Summary
Catalyst Pharmaceuticals reports record Q1 2023 revenues of $85.4 million, a 98% YoY increase. Affirms full-year revenue guidance of $375-385 million. Completes acquisition of FYCOMPA. Positive feedback from FDA on sNDA submission for FIRDAPSE. Continues efforts to acquire new products.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.19%
Tags
Catalyst Pharmaceuticals Inc

Nasdaq:CPRX

CPRX Rankings

CPRX Stock Data

2.75B
114.30M
6.31%
82.79%
5.13%
Biotechnology
Pharmaceutical Preparations
Link
United States
CORAL GABLES